

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01378K

APPLICATION NO.:

10/057,534

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APPLICANT:

Harry R. Davis et al.

FILING DATE:

01/25/2002

GROUP:

1617

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
S	AA	6,030,990	02/29/00	Maeda et al.			
S	AB	6,166,049	12/26/00	Smith et al.			
S	AC	2003/0153541	08/14/03	Dudley et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
S	AC	WO 01/14351	03/01/01	PCT				
	AD	WO 01/34148	05/17/01	PCT				
	AE	WO 01/60807	08/23/01	PCT				
	AF	WO 02/064094	08/22/02	PCT				
	AG	WO 02/08188	01/31/02	PCT				
	AH	WO 02/26729	04/04/02	PCT				
	AI	WO 03/039542	05/15/03	PCT				
	AJ	WO 03/074101	09/12/03	PCT				
S	AK	WO 03/088962	10/30/03	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

S	AL	Sorbera et al., Netoglitzzone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139
S	AM	Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259
S	AN	Berger et al., Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology &amp; Therapeutics</i> , 2002, 4:163-174


EXAMINER

DATE CONSIDERED


S. V. —

5/8/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PT-CD 1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01378K		SERIAL NO.: 10/057,534	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)				APPLICANT: Harry R. Davis, et al.			
				FILING DATE: January 25, 2002		GROUP: 1617	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SW	AA	5,021,461	06/04/91	Robinson et al.			
SW	AB	4,687,777	08/18/87	Meguro et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
SW	AC	WO 97/28149	08/07/97	PCT			
	AD	WO 99/22728	05/14/99	PCT			
	AE	WO 01/96347	12/20/01	PCT			
	AF	WO 02/26729	04/04/02	PCT			
	AG	WO 02/064094	08/22/02	PCT			
	AH	WO 95/35277	12/28/95	PCT			
	AI	WO 02/50027	06/27/02	PCT			
	AJ	WO 02/50060	06/27/02	PCT			
	AK	WO 02/50068	06/27/02	PCT			
	AL	WO 99/08501	02/25/99	PCT			
	AM	WO 94/26738	11/24/94	PCT			
	AN	EP 1 036 563 A1	09/20/00	EPO			
	AO	EP 0 753 298 A1	01/15/97	EPO			
SW	AP	FR 1103113	10/31/55	FRANCE			X (abs.)
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
SW	AQ	Stuart B. Rosenblum et al., Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, <i>J. Med. Chem.</i> 41:973-980 (1998)					
	AR	Gilbert R. Thompson et al., Novel lipid-regulating drugs, <i>Exp. Opin. Invest. Drugs</i> 9(11):2619-2628 (2000)					
	AS	T. Kosoglou et al., Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects on Apo CIII and LDL Subfractions, <i>Atherosclerosis</i> 2:89 (2001)					
	AT	Harry R. Davis et al., The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs, <i>Metabolism</i> 50 (10):1234-1241 (2001)					
	AU	Study Showed Ezetimibe Significantly Reduced Levels of LDL Cholesterol or "Bad" Cholesterol in Patients, Schering-Plough Press Release					
	AV	T. Kosoglou et al., Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe, <i>Atherosclerosis</i> (2):38 (2001)					
	AW	Remington's Pharmaceutical Sciences, 18 <sup>th</sup> ed. 1990 p. 1319, 1633-1647					
	AX	Baker S G et al., Treatment of homozygous familial hypercholesterolaemia with probucol, <i>South African Medical Journal</i> (1982)					
SW	AY	R. Milanese et al., Xantom E ipercolesterolemia: Prevalenza, Diagnosi e Terapia, <i>Chron. Derm.</i> 455-61 (1990)					
EXAMINER  S. V. [Signature]				DATE CONSIDERED  5/8/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

SERIAL NO.:

CV01378K

10/057,534

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APPLICANT:

Harry R. Davis et al.

FILING DATE:

01/25/2002

GROUP:

1615

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

5	AQ	ZETIA™ (ezetimibe) Tablets Package Insert (Merck/Schering-Plough Pharmaceuticals) (October 2002)
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.